Remove 2027 Remove Healthcare Provider Remove Sales
article thumbnail

9 Steps to Build Digital Healthcare Solutions that Meet Patient’s Growing Expectations

PM360

Patients now demand greater access to their health information, desire more communication with their healthcare providers, and seek personalized care tailored to their individual needs. Patients increasingly expect a seamless healthcare experience in which all their health information is integrated and easily accessible.

article thumbnail

4 Ways to Meet the Needs of an Increasing Health-conscious Audience

PM360

Consumers want companies to help them meet their health and wellness needs, including providing access to innovative products and services that will allow them to live healthier lives. Healthcare and pharma companies are watching this trend and refining their strategies to meet tomorrow’s health consumer.

Retail 97
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Making Sense of the Latest Changes to the Market Access Landscape

PM360

Most immediately, it will add confusion in the healthcare space,” explains Daniel Sontupe, Associate Partner, Managing Director, The Bloc Value Builders. This will create confusion in the marketplace and may possibly lead to delivery of misinformation to healthcare providers (HCPs) regarding a brand’s drug coverage,” Bambalas says.

article thumbnail

Specialty Treatments Require a New Approach to Affordability

PM360

aging population, a rise in the net per capita spending on specialty drugs, an increased life expectancy (apart from the impact of COVID), and the increasing prevalence of chronic diseases are expected to boost the specialty pharmaceuticals market to $352 billion by 2027. The Uses—and Costs—of Specialty Treatments Keep Rising A U.S.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. NICE has only allowed healthcare providers to prescribe continuous treatment of the drug for two years. Anti-obesity therapeutic landscape. million in Q3.

Medical 105
article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. NICE has only allowed healthcare providers to prescribe continuous treatment of the drug for two years. Anti-obesity therapeutic landscape. million in Q3.

Medical 98